SFI
ABEO icon

Susquehanna Fundamental Investments’s Abeona Therapeutics ABEO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-848
Closed -$22K – 1472
2020
Q3 		$22K Buy
848
+112
+15% +$7.06K ﹤0.01% 1344
2020
Q2 		$54K Buy
+736
New +$50.9K ﹤0.01% 937

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna Fundamental Investments's ABEO Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Abeona Therapeutics (ABEO) in Q4 2020, closing a stake of 848 shares — an estimated $22K sold.

Susquehanna Fundamental Investments first reported a position in ABEO in Q2 2020 and held it in 2 quarters. The position peaked at $54K in Q2 2020. 73 funds tracked by Wall St. Rank hold ABEO as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Abeona Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 848 Abeona Therapeutics shares in Q4 2020, an estimated $22K.
  • Susquehanna Fundamental Investments first reported a position in Abeona Therapeutics in Q2 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Abeona Therapeutics position peaked at $54K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.